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Plasmodium vivax resistance to antifolates is prevalent throughout Australasia and is caused by point
mutations within the parasite dihydrofolate reductase (DHFR)-thymidylate synthase. Several unique muta-
tions have been reported in P. vivax DHFR, and their roles in resistance to classic and novel antifolates are not
entirely clear due, in part, to the inability to culture P. vivax in vitro. In this study, we use a homologous system
to episomally express both wild-type and various mutant P. vivax dhfr (pvdhfr) alleles in an antifolate-sensitive
line of P. falciparum and to assess their influences on the susceptibility of the recipient P. falciparum line to
commonly used and new antifolate drugs. Although the wild-type pvdhfr-transfected P. falciparum line was as
susceptible to antifolate drugs as the P. falciparum parent line, the single (117N), double (57L/117T and
58R/117T), and quadruple (57L/58R/61M/117T) mutant pvdhfr alleles conferred a marked reduction in their
susceptibilities to antifolates. The resistance index increased with the number of mutations in these alleles,
indicating that these mutations contribute to antifolate resistance directly. In contrast, the triple mutant allele
(58R/61M/117T) significantly reversed the resistance to all antifolates, indicating that 61M may be a compen-
satory mutation. These findings help elucidate the mechanism of antifolate resistance and the effect of existing
mutations in the parasite population on the current and new generation of antifolate drugs. It also demon-
strates that the episomal transfection system has the potential to provide a rapid screening system for drug
development and for studying drug resistance mechanisms in P. vivax.
Of the four species of Plasmodium that commonly cause
malaria in humans, Plasmodium vivax is the most widely dis-
tributed and can account for up to 80 million cases annually
(25). Although P. vivax infections cause less mortality than P.
falciparum, they do cause a debilitating disease that contributes
to significant morbidity and economic loss in many regions
where P. vivax is endemic (25). This is compounded by fre-
quent relapses that can occur many times and for many months
after the initial infection (6, 16, 22).
Plasmodium vivax parasites are susceptible to most antima-
larial drugs. However, over the last 20 years there have been
many reports that highlight the significant increase in resis-
tance of P. vivax malaria to chloroquine, the recommended
first-line treatment of P. vivax, and/or sulfadoxine-pyri-
methamine (SP) (1, 7, 9, 13, 29, 31, 41, 42). Although the
determinant(s) for chloroquine resistance in P. vivax remains
elusive, a genetic basis for antifolate resistance in P. vivax has
been identified as polymorphisms in the P. vivax dihydrofolate
reductase (PvDHFR) active site, the same mechanism ob-
served in antifolate resistance in P. falciparum (2, 11, 12, 17, 18,
20, 21, 24, 39).
In P. falciparum, point mutations within DHFR have been
determined as the cause for antifolate resistance, such as py-
rimethamine and cycloguanil resistance (4, 5, 8, 30, 32–36, 44,
45). It has been shown that resistance to antifolates results
from the accumulation of mutations in the P. falciparum
DHFR, principally A16V, N51I, C59R, S108N or S108T, and
I164L.
A large number of point mutations have been identified in
PvDHFR, and some were reported to be prevalent in many
areas of P. vivax endemicity (2, 12, 18, 20, 21, 39). A particular
set of mutations (F57L  S58R  T61M  S117T) within the
P. vivax DHFR was shown to correlate with SP treatment
failures (18, 39) and to confer significant antifolate resistance
when transfected into antifolate-sensitive P. falciparum (28).
Resistance is due to alterations to the pyrimethamine binding
site of PvDHFR that reduces parasite-drug interactions (23,
28). However, the contribution of these PvDHFR mutations to
resistance to a variety of antifolates drugs is not clear.
Due to the difficulty in maintaining P. vivax in in vitro cul-
tures, most studies of the mutations within PvDHFR have been
limited to surrogate biological systems such as yeast and Esch-
erichia coli (17, 19, 24, 38). Although these systems have obvi-
ous experimental utility, they are different from Plasmodium in
many biological aspects, particularly in membrane structures
and transporters that can potentially affect the susceptibility to
drugs. A recent publication (28) showed that the pvdhfr-ts
quadruple mutant allele (57L  58R  61M  117T) that is
episomally expressed in P. falciparum provides significant pro-
tection against antifolates. This demonstrated an excellent po-
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tential of using P. falciparum as a biological system for the
transgenic expression of pvdhfr-ts alleles to assess DHFR-TS
interactions with antifolates.
We report here the use of this P. falciparum expression
system to assess the effect that specific mutations within the P.
vivax DHFR have on conventional and new-generation anti-
folate drugs. The findings improve our understanding of the
effect of various mutant pvdhfr alleles observed in the field on
the parasite responses to current and new generations of an-
tifolates, improve the prediction of malaria drug treatment
outcome, and provide a useful tool for drug development.
MATERIALS AND METHODS
Parasite lines. The P. falciparum lines D6 and TM91c235 were used in the
present study. D6 is susceptible to pyrimethamine, cycloguanil, and WR99210
(27) and was used as a recipient of various pvdhfr alleles. TM91c235 has qua-
druple mutations (51I/59R/108N/164L) in its DHFR and has been shown to be
susceptible to WR99210 but resistant to cycloguanil and pyrimethamine (26).
This line was used as an antifolate-resistant control. Parasite lines were cultured
continuously in a 4% hematocrit blood-LPLF RPMI 1640 (consisting of 0.0005
mg of para-aminobenzoic acid/liter, 0.01 mg of folate/liter, and L-glutamine;
Gibco, Grand Island, NY) supplemented with 10% human plasma, 25 mmol of
HEPES buffer/liter, 25 mmol of NaHCO3/liter, and gentamicin (25 mg/liter) and
were grown at 37°C in tissue culture flasks gassed with 90% N2, 5% O2, and 5%
CO2 (40).
Plasmid construction. The open reading frames (ORFs) from P. vivax dhfr-ts
(Table 1) were amplified by PCR using primers and conditions described previ-
ously (2, 39). Genomic DNA from P. vivax isolates containing various mutant
pvdhfr alleles (2) were used as templates. The pvdhfr triple mutant (58R/61M/
117T) allele was kindly provided by Carol Sibley (University of Washington,
Seattle). The plasmid construction was essentially performed as described earlier
(28) with minor modifications. The pvdhfr PCR product was inserted between the
P. falciparum dhfr-ts promoter and the P. falciparum thymidylate synthase gene,
followed by an hrp2 termination sequence. All plasmids except for the pvdhfr
quadruple mutant (57L/58R/61M/117T) had the 0.4-kb Saccharomyces cerevisiae
bsd ORF inserted, in frame, between the promoter and dhfr-ts ORF as described
previously (28) (Fig. 1).
Transfections. Red blood cells were electroporated (320 V, 950 F, 200 )
with 300 g of plasmid DNA and then added to synchronized D6 schizont-staged
parasites (10, 28). D6 parasites transfected with bsd-pvdhfr were selected with 2.5
ng/l of blasticidin (Invitrogen Corp.). D6 parasites transfected with the pvdhfr
quadruple mutant (57L/58R/61M/117T) were selected with 100 ng/l of py-
rimethamine (Hoffmann-La Roche, Switzerland). Parasites were first observed
by Giemsa-stained thin smears between 15 and 30 days, with growth rate and
morphology being indistinguishable from those of nontransfected parent D6 by
day 40. Transfected parasites remained under blasticidin or pyrimethamine pres-
sure except when being assayed by DHFR inhibitors. Plasmid DNA was recov-
ered from transfected parasites during each drug assay, and the plasmid-bound
dhfr was sequenced (data not shown) to ensure that additional mutations were
not introduced.
Copy number determination. The pvdhfr gene copy number for the pvdhfr
quadruple mutant (57L/58R/61M/117T) and the bsd copy number for the other
plasmids were estimated by a quantitative real-time PCR assay using the
MX3000P multiplex quantitative PCR system (Stratagene) according to proce-
dures similar to those described elsewhere (37). The primers used to quantify
pvdhfr were those used to amplify the pvdhfr quadruple mutant (57L/58R/61M/
117T) described previously (3). A single-copy gene encoding P. falciparum
EBA175 (GenBank accession no. MAL7P1.176) was used as a reference (nor-
malizer) gene for estimating either the pvdhfr or the bsd copy number. Primers
used to amplify fragments of bsd and the eba175 genes are listed in Table 2. The
copy numbers of the plasmids were determined based on the threshold cycle (CT)
values of pvdhfr and bsd using the CT method (37). The difference in the copy
numbers between different transfectant lines was determined and tested
(P value) by using a nonparametric comparison (Wilcoxon signed-rank test).
In vitro susceptibility studies. WR99210 was kindly supplied by Jacobus Phar-
maceutical Company (Princeton, NJ). Cycloguanil and clociguanil were supplied
by ICI Pharmaceuticals (Macclesfield, United Kingdom), and pyrimethamine
was supplied by Hoffmann-La Roche (Switzerland). All compounds were initially
dissolved in dimethyl sulfoxide and diluted in complete LPLF RPMI 1640. The
susceptibility assays were essentially performed as described previously (14) with
minor modifications. The parasite suspension (90 l/well) consisted of infected
erythrocytes (1.5% hematocrit, 0.7% parasitemia) in complete LPLF RPMI
1640. Parasites were challenged with dilutions of the drugs for 72 h. [3H]hypox-
anthine (Perkin-Elmer) was added after 48 h when parasites had already rein-
vaded the red blood cells and were at ring stages, and the parasites were har-
vested after 72 h. Incorporation of 3H (measured in cpm) was recorded for each
well, and the concentrations of drugs that inhibited 50% of parasite growth
(IC50s) were determined (28). All assays were performed in duplicate on at least
three different occasions. The IC50 was determined using nonlinear regression
analysis provided by Sigma Plot for Windows, version 11 (Systat Software, Inc.,
San Jose, CA).
TABLE 1. P. vivax dhfr ORFs transfected into D6 parasitesa
Plasmid
Amino acid mutation at position:
Country of origin
33 50 57 58 61 117 173
pvdhfr wild-type allele P N F S T S I East Timor
pvdhfr single mutant allele (117N) P N F S T N I East Timor
pvdhfr double mutant allele (58R/117T) P N F R T T I East Timor
pvdhfr double mutant allele (57L/117T) P N L S T T I Papua New Guinea
pvdhfr triple mutant allele (58R/61M/117T) P N F R M T I Indonesia
pvdhfr quadruple mutant allele (57L/58R/61M/117T) P N L R M T I Papua New Guinea
a Any changes from the wild-type allele are indicated in boldface. All isolates were obtained as previously described (2).
FIG. 1. Schematic illustration of the organization of P. falciparum
expression plasmid vector (28). The sizes of the boxes are not propor-
tional to the lengths of the genes.
TABLE 2. Primers used in the quantitative PCR to determine the
pvdhfr copy number
Primer Primer set Sequence (5–3)
BSD BSD F GCGACGGCCGCATCT
BSD R ACAAGGTCCCCCAGTAAAATGA
EB175 EB175 F CATCTGAAATGTCGCATAATAGTAGT
EB175 R GGTTCCCAAATCACCAACAGTT
Pvdhfr dhfrS (3) TCTGGGCAATAAGGGGACT
dhfrA (3) AGTTTCTACTTAGGCATTCCCTAT
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RESULTS
D6 parasites episomally expressing P. vivax dhfr-ts and their
susceptibility to antifolates. D6 parasites transfected with wild-
type and various mutant pvdhfr alleles were assayed to deter-
mine the direct effect that these alleles have on the parasites’
susceptibility to pyrimethamine, cycloguanil, clociguanil, and
WR99210 (Table 3 and Fig. 2).
D6 transfected with the P. vivax wild-type dhfr-ts (WT) had
a susceptibility profile similar to that of the parental D6 strain,
as observed earlier (28). This demonstrated that the WT was at
least as equally susceptible to antifolates as the wild-type P.
falciparum dhfr-ts. In contrast, D6 transfected with most of the
mutant P. vivax dhfr alleles were less susceptible to antifolates
than was the WT. D6 transfected with the P. vivax single
mutant pvdhfr (117N) was 46-fold less susceptible to py-
rimethamine, 6-fold less susceptible to clociguanil, and 6-fold
less susceptible to WR99210 than the WT and D6.
The D6 strains transfected with two double mutant pvdhfr
alleles—57L/117T and 58R/117T—were less susceptible to all
of the antifolates tested than the 117N allele. The 58R/117T
allele was more resistant to pyrimethamine and clociguanil but
more susceptible to cycloguanil and WR99210 than was the
57L/117T allele.
D6 transfected with the triple mutant pvdhfr allele (58R/
61M/117T) was more susceptible to the antifolates than D6
transfected with either single or double mutant alleles. The
quadruple mutant pvdhfr allele (57L/58R/61M/117T) con-
ferred a greater resistance to all of the antifolates than all of
the other pvdhfr mutant alleles and the native P. falciparum
quadruple mutant TM91c235. The 57L/58R/61M/117T mutant
was 8,497-fold more resistant to pyrimethamine than the WT
and 3-fold more resistant than TM91c235.
Copy number of episomes versus antifolate susceptibility.
The copy numbers of the episomally expressed pvdhfr in the
transfected D6 parasites were determined by quantitative PCR
after each drug assay was performed. As shown in Table 3, the
average copy number within the parasite population was found
to range between 0.5 and 9 copies per parasite over three
different time points. There was no significant difference in the
copy numbers between different transfectant parasite lines at
the time of the assay (P  0.576). Before the susceptibility
assays were conducted, the transfected parasites were taken off
selective drug pressure. A trend was observed that the longer
the transfected parasites were without drug pressure the lower
the copy number of the episomes per parasite (data not
shown).
DISCUSSION
This study demonstrates, for the first time, the effect that
specific point mutations within the P. vivax dhfr have on the
susceptibility to several DHFR inhibitors in a homologous
system by the transfection and episomal expression of the
various wild-type and mutant pvdhfr alleles in P. falciparum. It
provides direct evidence that commonly seen mutations in
pvdhfr confer resistance to antifolate drugs, with higher num-
bers of mutations often causing higher levels of resistance. It
also demonstrates that various mutations generate different
resistance profiles.
We observed that P. falciparum transfected with the wild-
TABLE 3. Susceptibility of parasites and transfected parasite lines to pyrimethamine, cycloguanil, clociguanil, and WR99210 and copy
number of episomes per parasitea
Origin of dhfr
Pyrimethamine Cycloguanil Clociguanil WR99210
Copy no.
IC50 (SD) RR IC50 (SD) RR IC50 (SD) RR IC50 (SD) RR
Native P. falciparum
lines
D6 0.028 (0.016),
0.112 (0.064)
1 0.118 (0.032),
0.468 (0.127)
0 0.021 (0.02),
0.066 (0.066)
1 0.166 (0.1),
0.384 (0.23)
2
TM91c235 142.61 (4.161),
573.42 (16.73)
2,592 116.4 (50),
462.45 (198)
50 3.16 (1.58),
9.99 (4.99)
144 0.339 (0.12),
0.784 (0.27)
5
D6 transfected with
various pvdhfr
alleles
Wild type 0.055 (0.0007),
0.221 (0.0003)
1 0.429 (0.1), 1.7
(0.4)
1 0.022 (0.007),
0.069 (0.022)
1 0.067 (0.03),
0.155 (0.069)
1 0.8–7
Single mutant
(117N)
2.5 (0.01), 10.05
(0.04)
46 0.81 (0.1), 3.22
(0.4)
2 0.067 (0.016),
0.211 (0.05)
6 0.427 (0.17),
0.988 (0.39)
6 1.83–1.85
Double mutant
(57L/117T)
3.66 (2.64),
14.72 (10.61)
67 2.77 (2.5), 11.05
(9.9)
6 0.219 (0.033),
0.692 (0.104)
10 1.5 (0.04), 3.47
(0.092)
22 0.7–9
Double mutant
(58R/117T)
6.26 (0.834),
25.17 (3.35)
114 1.699 (0.94),
6.75 (3.73)
4 0.582 (0.051),
1.84 (0.161)
26 0.69 (0.095),
1.6 (0.22)
10 0.5–6
Triple mutant
(58R/61M/117T)
2.81 (1.9),
11.29 (7.64)
51 0.587 (0.25),
2.332 (0.99)
1 0.073 (0.04),
0.23 (0.126)
3 0.105 (0.025),
0.243 (0.058)
2 0.8–4.5
Quadruple
mutant (57L/
58R/61M/117T)
467.34 (90),
1,879 (361)
8,497 320 (22.93),
1,271.4 (91.1)
746 56.44 (29),
178.5 (91.7)
2565 2.93 (0.36),
6.78 (0.833)
44 1.19–1.46
a IC50s are means of triplicate data points and are expressed as: mean nM  SD (first value), mean ng/ml  SD (second value). Values reflect the means of triplicate
data points. The relative resistance index (RR) was determined in comparison to D6 transfected with the pvdhfr wild-type allele. The copy number indicates the range
of pvdhfr copy numbers determined at three different time points.
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type pvdhfr was at least as susceptible to antifolates as the
parent strain D6, which is consistent with our earlier findings
(28). We further demonstrated here that this susceptibility to
antifolates was not affected by the copy number of the epi-
somes carrying the wild-type pvdhfr per parasite since the WT-
transfected parasite copy numbers ranged between 0.8 and 7
copies per parasite over three different time points without
significant changes in their susceptibility profiles. This may
result from a tight regulation of the parasite DHFR-TS expres-
sion level (43).
The in vitro susceptibility of the parasites transfected with
mutant pvdhfr alleles to antifolate drugs reduced significantly.
The single mutation of 117N conferred a marked (46-fold)
increase in resistance to pyrimethamine compared to the WT
pvdhfr-transfected line and moderate levels of reduced suscep-
tibility to cycloguanil, clociguanil, and WR99210. This effect is
consistent with that observed in P. falciparum resulting from
the homologous S108T mutation (15, 23), which was suggested
to be due to steric clashes between the pyrimethamine and
108N mutation (23).
The two pvdhfr alleles with double mutations (58R/117T and
57L/117T) that share one common mutation provided an op-
portunity to analyze the roles of the mutations that differ
between the two alleles. Both alleles conferred higher resis-
tance to all four antifolates than the WT- and single mutant
117N-transfected lines. The double mutant pvdhfr 58R/117T-
transfected line showed a similar susceptibility to cycloguanil
but a reduced susceptibility to pyrimethamine and clociguanil
compared to the 57L/117T-transfected line. The 58R/117T
transfectant line was more susceptible to WR99210 than was
the 57L/117T transfectant line. Since both of these double
mutants have the same 117T mutation, we hypothesize that the
57L mutation is responsible for the greater level of resistance
to cycloguanil and particularly to WR99210. This result is sup-
ported by an earlier report (28) of a structural study that the
57L mutation clashes sterically with cycloguanil and WR99210
FIG. 2. In vitro susceptibility of P. falciparum D6 and D6 transfectant parasite lines episomally expressing various pvdhfr mutants to DHFR
inhibitors: pyrimethamine (top left panel), cycloguanil (top right panel), clociguanil (bottom left panel), and WR99210 (bottom right panel). The
symbols represent the means of triplicate data points.
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more than with pyrimethamine because this drug has a more
flexible -CH2-CH3 group in the same position.
Interestingly, we observed that the triple pvdhfr mutant
(58R/61M/117T) conferred much higher susceptibility to all of
the antifolates tested than the double and single mutant pvdhfr
alleles, almost reversing the susceptibility close to that of the
parasite transfected with wild-type pvdhfr. This mutation is
specific to P. vivax DHFR. This suggests that the T61M muta-
tion may be a compensatory mutation that occurred after the
development of resistance mutations (58R, 117T) to balance
the damaging effect of resistant mutations on the enzyme ac-
tivity. Although T61M may not directly affect the binding of
the antifolate drugs from binding to the enzyme, this change
may be essential before parasites developing additional muta-
tions can become quadruple and quintuple mutants.
The quadruple pvdhfr mutant (57L/58R/61M/117T) showed
the greatest level of resistance to the antifolates tested, and
clinically this combination of mutations has been linked to
treatment failure with SP (17, 18, 39). Molecular modeling and
energy minimization studies (23, 28) have provided supporting
evidence that the combination of these specific point mutations
57L, 58R, 61M, and 117T greatly hinders the binding of anti-
folates to the parasite enzyme.
In summary, we identified here a strong correlation between
specific point mutations within pvdhfr and resistance to various
antifolate drugs and provided novel insights into the role of
these mutations: some contributing directly to resistance and
some to enhancing the fitness of the mutant enzyme. These
findings help elucidate the mechanism of antifolate resistance
and the effect of existing mutations in the parasite population
on current and new generations of antifolate drugs. For in-
stance, the system can be used directly to assess the action and
effect of the highly potent WR99210 series of antifolates on
various existing P. vivax DHFR mutant alleles and thus help to
speed up the drug development process. A similar approach
could be used to identify and confirm other potential drug
targets in P. vivax. Therefore, the episomal transfection system
has the potential to provide a rapid screening system for drug
development and for studying drug resistance mechanisms in
P. vivax in the absence of a stable long-term in vitro culture
system for P. vivax.
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